Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission

NCT04506086 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04506086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04506086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Terminated
Start date
August 26, 2021
Completion date
September 16, 2024
Enrollment
10 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

b-precursor acute lymphoblastic leukemia